Drug Profile
Research programme: stem cell therapy - Benitec/ReNeuron
Alternative Names: ExoPr0Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Benitec Biopharma; ReNeuron
- Class Exosome therapies; Small interfering RNA; Stem cell therapies
- Mechanism of Action Gene silencing; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in Australia (IV)
- 28 Jul 2019 No recent reports of development identified for research development in Cancer in United Kingdom (IV)
- 17 Jul 2019 ReNeuron has patent protection for neural stem cell exosome in the treatment of Glioma in Japan